Hematologic Malignancy
Myeloid Leukemia
CI-CAN-00001251Explore in graph →
Hematologic862 active trials22 approved drugs599 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001251Explore in graph →
Clinical trials
3,528 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (617)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05272293 | Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Children/Young Adults With AML | unknown | Phase 1 / Phase 2 | 15 | Belarusian Research Center for Pediatric Oncology, Hematology and ImmunologyOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT05334693 | Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children/Young Adults With AML | unknown | Phase 1 / Phase 2 | 15 | Belarusian Research Center for Pediatric Oncology, Hematology and Immunology |
| 1 |
| Aug 28, 2024 |
| clinicaltrials |
| NCT04365179 | Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML | unknown | Phase 1 | 18 | Immune System Key LtdINDUSTRY | 1 | Jul 10, 2024 | clinicaltrials |
| NCT02061800 | CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant | unknown | Phase 1 / Phase 2 | 14 | Diane GeorgeOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT05758610 | A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients | unknown | Phase 1 | 60 | Shengke Pharmaceuticals (Jiangsu) Limited, ChinaINDUSTRY | 1 | May 8, 2024 | clinicaltrials |
| NCT06367673 | Natural Killer(NK) Cell Therapy Targeting CLL1 or CD33 in Acute Myeloid Leukemia | unknown | Phase 1 | 24 | Zhejiang UniversityOTHER | 1 | Apr 18, 2024 | clinicaltrials |
| NCT04358393 | A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS | unknown | Phase 1 / Phase 2 | 69 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Feb 1, 2024 | clinicaltrials |
| NCT06218771 | A Study of TQB3454 Tablets in Patients With Blood Tumors | unknown | Phase 1 / Phase 2 | 80 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jan 23, 2024 | clinicaltrials |
| NCT04284228 | Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT | unknown | Phase 1 / Phase 2 | 22 | NexImmune Inc.INDUSTRY | 1 | Jan 16, 2024 | clinicaltrials |
| NCT03896854 | CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | unknown | Phase 1 / Phase 2 | 15 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Nov 29, 2023 | clinicaltrials |
| NCT04964518 | A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML) | unknown | Phase 1 / Phase 2 | 24 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Oct 25, 2023 | clinicaltrials |
| NCT06049667 | A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies | unknown | Phase 1 | 72 | Nanjing Chia-tai Tianqing PharmaceuticalINDUSTRY | 1 | Sep 22, 2023 | clinicaltrials |
| NCT06027853 | Natural Killer(NK) Cell Therapy Targeting CLL1 in Acute Myeloid Leukemia | unknown | Phase 1 | 24 | Zhejiang UniversityOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT06008405 | Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy | unknown | Phase 1 | 48 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 6, 2023 | clinicaltrials |
| NCT05982756 | Bortezomib Combined With DAG Regimen in the Treatment of Refractory/Relapsed AML | unknown | Phase 1 | 40 | Zhongnan HospitalOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT03867682 | Venetoclax and Lintuzumab-Ac225 in AML Patients | unknown | Phase 1 / Phase 2 | 38 | Actinium PharmaceuticalsINDUSTRY | 1 | Aug 4, 2023 | clinicaltrials |
| NCT05226468 | An Early Phase Study of NEI-01 in Patients With Solid Tumors or Acute Myeloid Leukemia | unknown | Phase 1 | 24 | New Epsilon Innovation LimitedINDUSTRY | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05949762 | Safety and Efficacy of Venetoclax in Combination With Azacitidine and HA Regimen in the Treatment of AML in the Elderly | unknown | Phase 1 / Phase 2 | 45 | ZePing ZhouOTHER | 1 | Jul 18, 2023 | clinicaltrials |
| NCT05893472 | A Study on the Efficacy and Safety of Venetoclax Combined With HAA Regimen in Newly Diagnosed Young AML. | unknown | Phase 1 / Phase 2 | 45 | ZePing ZhouOTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT05140811 | A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome | unknown | Phase 1 / Phase 2 | 126 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | May 24, 2023 | clinicaltrials |
| NCT05471323 | Phase I Clinical Trial of RC1012 Injection in Patients With r/r AML | unknown | Phase 1 | 36 | Guangdong Ruishun Biotech Co., LtdINDUSTRY | 1 | May 19, 2023 | clinicaltrials |
| NCT05858814 | RC1012 Injection (Allo-DNT Cells) for the Prevention of Relapse in AML Patients After Allo-HSCT | unknown | Phase 1 / Phase 2 | 72 | Guangdong Ruishun Biotech Co., LtdINDUSTRY | 1 | May 19, 2023 | clinicaltrials |
| NCT04471064 | A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid Leukemia | unknown | Phase 1 | 60 | Shijiazhuang Yiling Pharmaceutical Co. LtdINDUSTRY | 1 | May 18, 2023 | clinicaltrials |
| NCT04265963 | CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 45 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT04272125 | Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 40 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05697510 | Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acute Myeloblastic Leukaemia (AML) With Poor Prognosis: SILTUXILAM(SILTUXILAM) | unknown | Phase 1 | 12 | Nantes University HospitalOTHER | 1 | Apr 6, 2023 | clinicaltrials |
| NCT05503355 | A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML | unknown | Phase 1 / Phase 2 | 80 | BioSight Ltd.INDUSTRY | 1 | Apr 4, 2023 | clinicaltrials |
| NCT05448599 | A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS | unknown | Phase 1 / Phase 2 | 120 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Mar 15, 2023 | clinicaltrials |
| NCT05740917 | To Evaluate the Phase I Clinical Study of XZB-0004 in Patients With AML and MDS | unknown | Phase 1 | 82 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 23, 2023 | clinicaltrials |
| NCT04669067 | TL-895 and KRT-232 Study in Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 18 | Telios Pharma, Inc.INDUSTRY | 8 | Feb 17, 2023 | clinicaltrials |
| NCT05665075 | Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia | unknown | Phase 1 | 19 | Zhejiang UniversityOTHER | 1 | Jan 3, 2023 | clinicaltrials |
| NCT05665114 | Natural Killer(NK) Cell Therapy in r/r AML | unknown | Phase 1 | 18 | Zhejiang UniversityOTHER | 1 | Jan 3, 2023 | clinicaltrials |
| NCT03855371 | Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS(PANDA-T0) | unknown | Phase 1 | 5 | Ruijin HospitalOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT05497310 | Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL | unknown | Phase 1 / Phase 2 | 15 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT05587088 | Evaluation of the Safety and Efficacy of Esperanza Extract (PA001)(PA001) | unknown | Phase 1 / Phase 2 | 82 | Hospital Universitario San IgnacioOTHER | 1 | Oct 19, 2022 | clinicaltrials |
| NCT05577611 | An Open, Single Center, Randomized Controlled Clinical Study of UCB (Cord Blood) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) | unknown | Phase 1 | 57 | Zhongnan HospitalOTHER | 1 | Oct 13, 2022 | clinicaltrials |
| NCT03825367 | Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML | unknown | Phase 1 / Phase 2 | 13 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05488132 | Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML) | unknown | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT05473221 | Evaluate the Safety and Efficacy of CD33 CAR-T in Patients With R/R AML | unknown | Phase 1 | 20 | Zhejiang UniversityOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT05467202 | Evaluate the Safety and Efficacy of CLL1 CAR-T in Patients With R/R AML | unknown | Phase 1 | 20 | Zhejiang UniversityOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT05467254 | Evaluate the Safety and Efficacy of CLL1+CD33 CAR-T in Patients With R/R AML | unknown | Phase 1 | 20 | Zhejiang UniversityOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT05463640 | Evaluate the Safety and Efficacy of ADGRE2 CAR-T in Patients With R/R AML | unknown | Phase 1 | 20 | Zhejiang UniversityOTHER | 1 | Jul 19, 2022 | clinicaltrials |
| NCT04632316 | A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 33 | Glycostem Therapeutics BVINDUSTRY | 5 | Jun 21, 2022 | clinicaltrials |
| NCT04886206 | Injection of Lymphocytes From Haplo-identical Donor Following Chemotherapy in Patients With High-risk Acute Myeloblastic Leukemia Not Eligible for an Allogeneic Hematopoietic Stem Cell Transplantation(ILDA) | unknown | Phase 1 | 12 | Nantes University HospitalOTHER | 1 | May 11, 2022 | clinicaltrials |
| NCT04709458 | Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis | unknown | Phase 1 | 10 | Taiga Biotechnologies, Inc.INDUSTRY | 2 | May 3, 2022 | clinicaltrials |
| NCT05333705 | Donor Immune Cell Therapy for Acute Myeloid Leukemia | unknown | Phase 1 | 15 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Apr 19, 2022 | clinicaltrials |
| NCT04764513 | Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT | unknown | Phase 1 / Phase 2 | 20 | Chinese PLA General HospitalOTHER | 1 | Mar 28, 2022 | clinicaltrials |
| NCT05297123 | Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid | unknown | Phase 1 | 30 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Mar 28, 2022 | clinicaltrials |
| NCT04835584 | KRT-232 and TKI Study in Chronic Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 109 | Kartos Therapeutics, Inc.INDUSTRY | 8 | Mar 21, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Aug 28, 2024source: clinicaltrials